![Ozempic supply to remain limited in 2025]()
|
Ozempic supply will continue to be limited until the end of next year,
according to the latest advice from Novo Nordisk, Ozempic's supplier.
1 hour ago
from: Diabetes Australia
Continue reading...
Anti-obesity medication, Diabetes, GLP-1 receptor agonist, Novo Nordisk, Semaglutide, Shortage, Weight loss
|
- Weight-loss drug landscape to change markedly in 2025, bank suggests
A new, more powerful generation of weight-loss drugs could be about the
change the landscape for weight-loss treatments, according to...
from: Proactive financial news
|
- Why the investor craze for Ozempic and rival weight-loss drugs may resume
next year
Novo Nordisk's takeover of Catalent and the Danish firm's push to launch a
new generation of drugs could boost the importance of GLP...
from: MarketWatch
|
- Ozempic shortage to continue in 2025
Diabetes medication to remain in short supply throughout 2025, manufacturer
warns Efforts to boost the production of Ozempic (semaglutide)...
from: Australian Journal of Pharmacy
|
- For people who couldn’t get Ozempic or Wegovy, 2025 could be your year (if
you can afford it)
It's quickly become evident that GLP-1 drugs for diabetes, weight loss, and
more are the new wonder drugs—if only people could get them.
from: KTLA
|
- For people who couldn’t get Ozempic or Wegovy, 2025 could be your year (if
you can afford it)
It's quickly become evident that GLP-1 drugs for diabetes, weight loss, and
more are the new wonder drugs—if only people could get them.
from: Yahoo
|
|
